Comprehensive clinical evaluation of empagliflozin in the treatment of type 2 diabetes mellitus
10.12173/j.issn.1005-0698.202503058
- VernacularTitle:恩格列净治疗2型糖尿病的临床综合评价
- Author:
Bei ZHANG
1
;
Qingxia XUE
1
;
Lu CHEN
1
;
Jiaojiao CHEN
1
;
Huiyuan ZHANG
1
;
Shengjun MU
1
;
Fudong SUN
1
;
Quan ZHAO
1
Author Information
1. 烟台毓璜顶医院药学部(山东烟台 264000)
- Publication Type:Journal Article
- Keywords:
Empagliflozin;
Dapagliflozin;
Type 2 diabetes mellitus;
Comprehensive clinical evaluation
- From:
Chinese Journal of Pharmacoepidemiology
2025;34(10):1127-1139
- CountryChina
- Language:Chinese
-
Abstract:
Objective To conduct a multidimensional and multi-level evaluation of the comprehensive clinical value of empagliflozin in the treatment of type 2 diabetes mellitus.Methods Based on the National Essential Medicines List(2018 Edition),dapagliflozin was selected as the control.A comprehensive clinical evaluation index system was established through literature review,focus group interviews and in-depth expert interviews,encompassing six dimensions:safety,efficacy,economy,suitability,innovation,and accessibility.The Delphi method and hierarchical direct weighting method were used to screen indicators and determine their weights.Evidence for each indicator was collected and integrated both qualitatively and quantitatively through literature research,real-world studies,and pharmacoeconomic evaluations.Experts scored the indicators based on the collected evidence,and a total score for the comprehensive clinical evaluation of empagliflozin was calculated by combining these scores with indicator weights,followed by a comparative analysis with dapagliflozin.Results A comprehensive clinical evaluation of empagliflozin in the treatment of type 2 diabetes mellitus was successfully established,consisting of 6 primary indicators,14 secondary indicators,and 41 tertiary indicators.The overall evaluation score for empagliflozin was 90.35,and 89.47 for dapagliflozin.Conclusion The comprehensive clinical value of empagliflozin in the treatment of type 2 diabetes mellitus is slightly higher than that of dapagliflozin.This finding can serve as a reference for rational clinical drug use and related decision-making.
